U-GRCL

Q:GRCL - GRACELL BIOTECHNOLOGIES INC SPON ADS EACH REP 5 ORD SHS - https://ir.gracellbio.com/

05:36:42 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
GRCL - Q	0.1	2.59	·	3.09	0.1	2.83	-0.21	-6.9	127.0	330	591	2.94 3.09 2.83	6.99 1.40	Sep 25	Sep 19	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market: Nasdaq -- Bid Tick: Down -- UPC Restricted: No

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Options · Portfolio

Recent Trades - Last 10 of 591

More trades...

Time ET	Ex	Price	Change	Volume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2023-09-19 09:22	U:GRCL	News Release200	Gracell Biotechnologies ¢ € ™ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
2023-09-14 09:15	U:GRCL	News Release200	Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
2023-09-06 08:00	U:GRCL	News Release200	Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting

Date ET

Symbol

Type

Headline

2023-09-19 09:22

U:GRCL

News Release

Gracell Biotechnologies ¢ € ™ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders

2023-09-14 09:15

U:GRCL

News Release

Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

2023-09-06 08:00

U:GRCL

News Release

Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting